

#### **Board of Directors**



**Andy Coupe** 



Carol Campbell



David McClatchy



Fiona Oliver



Dan Coman

#### **Marlin Team**



Sam Dickie Snr Portfolio Manager



Chris Waters
Snr Investment
Analyst



Charles Barty Investment Analyst



Wayne Burns Corporate Manager

#### Agenda

- Preliminary matters
- Chair's Overview
- Manager's Review
- Q&A
- Annual Meeting Resolutions



### Chair's Overview

#### Marlin's Investment Objectives

#### **Absolute Returns**

Achieve a high real rate of return, comprising both income and capital growth within acceptable risk parameters.

#### **Diversified Portfolio**

Access to a diversified portfolio of international quality, growth stocks in a single tax-efficient vehicle.



#### 2025 Overview

Net profit	Dividend	NAV per share	Share price
<b>\$0.3m</b> (2024: \$37.2m)	<b>8.01</b> cps (2024: 7.59cps)	<b>\$0.95</b> (2024: \$1.03)	<b>\$0.91</b> (2024: \$0.96)
Total shareholder return *	Dividend return #	Adjusted NAV return *	Share price (discount) to NAV
<b>+2.8%</b> (2024: +13.8%)	+8.5% (2024: +7.9%)	<b>+0.2%</b> (2024: +19.5%)	(4.2%) (2024: 6.7%)

<sup>\*</sup>These metrics are Non-GAAP measures calculated in accordance with the methodology described in the Marlin Non-GAAP Financial Information Policy which is available on the Marlin website.

<sup>#</sup> Dividend return – how much Marlin pays out in dividends each year relative to its average share price during the period. (Dividends paid by Marlin may include dividends received, interest income, investment gains and/or return of capital).

<sup>^</sup>Share price (discount) / premium to NAV (excluding warrants).

#### 2025 Overview - Continued

For the year ended 30 June	12 months	3 years (annualised)	5 years (annualised)
Adjusted NAV return *	+0.2%	+10.9%	+7.3%
Gross Performance *	+2.7%	+13.7%	+10.1%
Benchmark Index ^	+14.9%	+15.1%	+12.9%

<sup>\*</sup>These metrics are Non-GAAP measures calculated in accordance with the methodology described in the Marlin Non-GAAP Financial Information Policy which is available on the Marlin website.


<sup>^</sup> Benchmark Index: S&P Large Mid Cap/S&P Small Cap Index (50% hedged to NZD)

### **Earnings Per Share**

Earnings Per Share	2025	2024	2023	2022	2021
Basic Earnings per Share (cents)	0.15	17.59	11.63	-31.34	35.55
Diluted Earnings Per Share (cents)	0.15	17.59	11.63	-31.34	38.60

#### Movements in Shareholders' Funds

12 Months to 30 June 2025 (\$m)



### **Quarter 1, 2026**

1 July – 30 September 2025		
Net profit \$2.5m	NAV per share \$0.94	
Adjusted NAV Return +1.2%	Benchmark Index +10.2%	
Share price \$0.95	Total shareholder return 5.9%	
	m	

growing globally

## Closing Remarks



## Manager's Review

Sam Dickie




#### Agenda

- 1. Review of markets in 2025
- 2. Company performance
- 3. Portfolio activity and positioning
- 4. Outlook

### 1. Review of markets in 2025



#### Global markets: solid returns in Marlin's 2025 year



MSCI World: +16%


US (S&P 500): +15%


AU (ASX 200): +14%


NZ (NZX 50): +8%



## Fundamentals: Moderate inflation, GDP rebounding, growing earnings








growing globally



#### Global markets: caution lies under the rally's hood





UBS AI winners index versus Global Benchmark

#### Higher risk companies outperformed






### 2. Portfolio Performance





#### While Marlin posted a small positive return, it was disappointing in a relative sense



<sup>\*</sup> S&P Large Mid Cap/S&P Small Cap Index (hedged 50% to NZD)

#### Relative performance is volatile over time






## S T E P P



#### Performance impacted by sector, stock and style

#### Split of impact on relative performance



#### Top 5 performing sectors (price move %)

Telecommunication Services	36%
Banks	34%
Financial Services *	34%
Insurance	30%
Utilities	26%


#### Bottom 5 performing sectors

Health Care Equipment & Services *	6%
Consumer Durables & Apparel *	4%
Energy	-1%
Household & Personal Products	-2%
Pharmaceuticals, Biotechnology & Life Sciences *	-4%

<sup>\*</sup> Estimated impact using UBS high-quality index underperformance


<sup>\*</sup> Sectors owned by Marlin

#### Performance by company in FY2025



■ Contribution (NZD)


#### Healthcare – what happened? And where are we now?




#### Danaher's Drug Discovery Solutions




#### Floor & Décor: taking market share vs abnormal sector headwinds








#### META and Netflix: flexing their scale -> driving customer stickiness





# 3. Portfolio activity and positioning



#### Changes to the Marlin portfolio

#### **Additions**






















**DOLLAR GENERAL** 



#### Marlin portfolio: higher quality, higher growth



## 4. Outlook



#### Global economy been resilient, but risks remain

- × Equity valuations elevated
- Labour market cooling
- X Geopolitical instability
- ✓ US economy robust
- Strong corporate earnings
- ✓ Al capex super cycle
- Central banks are cutting interest rates



### General Questions from Shareholders

(not relating to resolutions)



### **Annual Meeting**

2025 resolutions



#### **Matters of Business**

- Annual Report
- Resolutions:
  - -Re-elect Fiona Oliver
  - -Elect Dan Coman
  - -Auditor remuneration



### 2025 Annual Meeting Resolutions

- Introduce and propose
- Discussion, questions
- Lodge your vote



## Resolution 1 Re- election of Fiona Oliver

## To re-elect Fiona Oliver as a Director of Marlin Global Limited





## Resolution 2 Election of Dan Coman

## To elect Dan Coman as a Director of Marlin Global Limited





## Resolution 3 Auditor Remuneration

That the Board of Directors be authorised to fix the remuneration of the auditor for the ensuing year



#### Conclusion

- Complete and sign voting paper
- Voting papers in the voting boxes
- If you need a voting paper please see Computershare
- Results to NZX



